|A gallotannin-rich fraction from Caesalpinia spinosa (Molina) Kuntze displays cytotoxic activity and raises sensitivity to doxorubicin in a leukemia cell line.|
|Jump to Full Text|
|PMID: 22490328 Owner: NLM Status: MEDLINE|
|BACKGROUND: Enhancement of tumor cell sensitivity may help facilitate a reduction in drug dosage using conventional chemotherapies. Consequently, it is worthwhile to search for adjuvants with the potential of increasing chemotherapeutic drug effectiveness and improving patient quality of life. Natural products are a very good source of such adjuvants.
METHODS: The biological activity of a fraction enriched in hydrolysable polyphenols (P2Et) obtained from Caesalpinia spinosa was evaluated using the hematopoietic cell line K562. This fraction was tested alone or in combination with the conventional chemotherapeutic drugs doxorubicin, vincristine, etoposide, camptothecin and taxol. The parameters evaluated were mitochondrial depolarization, caspase 3 activation, chromatin condensation and clonogenic activity.
RESULTS: We found that the P2Et fraction induced mitochondrial depolarization, activated caspase 3, induced chromatin condensation and decreased the clonogenic capacity of the K562 cell line. When the P2Et fraction was used in combination with chemotherapeutic drugs at sub-lethal concentrations, a fourfold reduction in doxorubicin inhibitory concentration 50 (IC50) was seen in the K562 cell line. This finding suggested that P2Et fraction activity is specific for the molecular target of doxorubicin.
CONCLUSIONS: Our results suggest that a natural fraction extracted from Caesalpinia spinosa in combination with conventional chemotherapy in combination with natural products on leukemia cells may increase therapeutic effectiveness in relation to leukemia.
|Diana M Castañeda; Luis Miguel Pombo; Claudia Patricia Urueña; John Fredy Hernandez; Susana Fiorentino|
Related Documents :
|1769008 - Effect of insulin receptor down regulation on insulin-stimulated thymidine incorporatio...
1082488 - Binding of components of the properdin system to cultured human lymphoblastoid cells an...
9034128 - Activins and activin receptors in cell growth.
8882288 - Effects of insulin-like growth factors and binding protein 1 on bovine granulosa cell d...
25051398 - Effects of lentivirus-mediated rnai knockdown of nedd9 on human lung adenocarcinoma cel...
3621138 - Use of elevated pressure to promote the difference in permeability of adriamycin and he...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-04-10|
|Title: BMC complementary and alternative medicine Volume: 12 ISSN: 1472-6882 ISO Abbreviation: BMC Complement Altern Med Publication Date: 2012|
|Created Date: 2012-05-16 Completed Date: 2012-07-27 Revised Date: 2013-06-26|
Medline Journal Info:
|Nlm Unique ID: 101088661 Medline TA: BMC Complement Altern Med Country: England|
|Languages: eng Pagination: 38 Citation Subset: IM|
|Grupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.|
|APA/MLA Format Download EndNote Download BibTex|
Antineoplastic Agents / pharmacology, therapeutic use*
Caesalpinia / chemistry*
Caspase 3 / metabolism
Cell Line, Tumor
Chromatin / drug effects
Doxorubicin / pharmacology, therapeutic use*
Hydrolyzable Tannins / pharmacology, therapeutic use*
Inhibitory Concentration 50
Leukemia / drug therapy*, metabolism
Mitochondria / drug effects
Plant Extracts / pharmacology, therapeutic use*
|0/Adjuvants, Pharmaceutic; 0/Antineoplastic Agents; 0/Chromatin; 0/Hydrolyzable Tannins; 0/Plant Extracts; 23214-92-8/Doxorubicin; EC 3.4.22.-/Caspase 3|
Journal ID (nlm-ta): BMC Complement Altern Med
Journal ID (iso-abbrev): BMC Complement Altern Med
Publisher: BioMed Central
Copyright ©2012 Castañeda et al; licensee BioMed Central Ltd.
Received Day: 27 Month: 9 Year: 2011
Accepted Day: 10 Month: 4 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 10 Month: 4 Year: 2012
Volume: 12First Page: 38 Last Page: 38
Publisher Id: 1472-6882-12-38
PubMed Id: 22490328
|A gallotannin-rich fraction from Caesalpinia spinosa (Molina) Kuntze displays cytotoxic activity and raises sensitivity to doxorubicin in a leukemia cell line|
|Diana M Castañeda1||Email: email@example.com|
|Luis Miguel Pombo2||Email: firstname.lastname@example.org|
|Claudia Patricia Urueña1||Email: email@example.com|
|John Fredy Hernandez1||Email: firstname.lastname@example.org|
|Susana Fiorentino1||Email: email@example.com|
1Grupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia, Carrera 7 N. 43-82 Building 52, Office 608
2Grupo de Farmacología Vegetal, Fundación Universitaria Juan N. Corpas, Bogotá, Colombia, Carrera 111 # 159A61
Caesalpinia spinosa is a shrub commonly named dividivi. It is acknowledged to have antimicrobial and antioxidant activity, and is traditionally known for its antitumor activity . An ethanol extract from the fruit of C.spinosa has been proven to have antimicrobial activity against gram-positive and gram-negative bacteria, probably due to the presence of hydrolysable tannins in the fruits . Hydrolysable tannins are a group of gallic acid esters associated with polyols (glucose, glucitol, shikimic acid, quinic acid and quercitol, among others), where the galloyl groups can be further cross-linked by etherification or oxidation to form complex structures. The gallotannins (gallic acid esters) are the simplest hydrolysable tannins, were 1,2,3,4,6-penta-O-galloyl-β-D-glucose (pentagalloyl glucose [PGG]) is the prototype and central compound of the biosynthetic pathway . The presence of PGG, as well as gallotannins as mono, di or tri-galloylquinic acids, have been reported in Caesalpinia species corresponding to 40% to 60% of the fruit composition, depending upon their ecological habitat .
Gallic acid and its derivatives have proven selective antitumor activities, such as: reduction in biochemical markers associated with skin cancer ; cell death induction in several cancer cell lines, including leukemia [6,7], murine myeloma  and squamous carcinoma . In addition, a beverage containing epigallocatechin gallate (EGCG) has been reported to promote tumor regression in patients with low-grade lymphomas . Galloylquinic derivatives, such as 4,5-di-O-galloylquinic acid, have shown moderate cytotoxicity against melanoma cells (RPMI-7951) but not in other cell lines . Extensive studies have been carried out on PGG and have demonstrated that this compound has a number biological activities related to cancer therapy and prevention, such as antiangiogenic, antiproliferative, anti-inflammatory and antioxidant . However, there are limited studies supporting the use of polyphenols in the treatment of hematological malignancies, and even fewer involving hydrolysable polyphenols. In the present study, taking into account that polyphenol antioxidant activity has been clearly implicated in the control of these malignancies , and that C.spinosa has a high content of polyphenols and is widely distributed in our country, we have evaluated the anti-tumor activity of C.spinosa pod extracts and complex fractions using the erythroleukemia cell line (K652) as a model of hematological malignancy.
C.spinosa pods were collected in Villa de Leyva, Boyacá, Colombia in March 2007 and identified by Luis Carlos Jiménez from the Colombian National Herbarium; voucher specimen number COL 523714.
Three kg of fresh pods from C.spinosa were dried under airflow in a solar oven at 35°C and ground down to obtain 1.8 kg of plant material. Subsequently the plant material was extracted with ethanol (96%, 10 L) in a recirculating percolator (twice per day) over a period of 10 days. The ethanol crude extract (80 g) was concentrated under vacuum, trapped on silica gel and excess humidity removed at 25°C. Afterwards, the ethanol extract was fractionated with the following solvents: petroleum ether (1.5 L); chloroform (2 L); ethyl acetate (2 L); ethanol (2 L) and water (2 L) (aqueous fraction). From the ethyl acetate fraction we obtained an abundant precipitate which we named (P2Et). This corresponded to 2.78% of the ethanol extract and a supernatant which we named (S2Et) corresponded to 1.11%. The P2Et, S2Et and aqueous fractions were selected for biological testing based on their cytotoxic activity. The extraction protocol was performed three times and the chromatographic profiles of the components were verified.
The quality control carried out on the P2Et fraction gave the following results: foreign matter less than 2%; total ash less than 8%; ash that was insoluble in hydrochloric acid less than 1%; no evidence of heavy metals and pesticides. These result met the British Herbal Pharmacopoeia quality parameters.
Fraction characterization was determined by means of standard phytochemical tests. In the total ethanol extract the presence of alkaloids or nitrogen compounds were not identified using Dragenddorff, Valser, Reineckate and Mayer's reagents. The Shinoda test (Mg in HCl) was positive suggesting the presence of flavanones, flavanonols, flavones, flavonols or isoflavones. Hydrogen peroxide evidenced the presence of naphthoquinones and/or anthraquinones. The presence of steroids was demonstrated using Liebermann Burchard reagent. Low concentrations of steroidal saponins and/or triterpenoids were detected using hemolysis and foam tests. In order to assess the presence of anthraquinone glycosides, Borntrager's reaction (treatment with ammonia solution) was used. The presence of tannins was verified using ferric chloride solution, gelatin and lead acetate . P2Et, S2Et and aqueous fractions exhibited the presence of leucoanthocyanidins, the absence of quinones and a significant tannin content, especially in P2Et fraction.
Chromatographic analysis was carried out on TLC aluminum sheets (10 × 5 cm) (Merck) silica gel 60 F 254. Three solvent systems were used: Petroleum ether - ethyl acetate - formic acid (40:60:1); chloroform - ethyl acetate - acetic acid (50:50:1); and toluene - acetonitrile - formic acid (70:30:1). After basic hydrolysis, the P2Et and S2Et fractions were dissolved in methanol (1%) and detected using UV (254 nm), FeCl3 (10%) and vanillin-sulfuric acid (VS)/110°C. Gallic acid was used as a positive control.
HPLC analysis was carried out in an Alliance 2795 (Waters®, UK) with a PDA detector (996). A Sunfire (Waters) column C18 - 2.1 × 150 mm × 5 μm was used, with a flow rate of 0.25 ml/min and a linear gradient from 95% solvent A (H2O + 1%CH3COOH) and 5% solvent B (CH3CN) to 60% in solvent A and 40% in solvent B, over a period of 25 min. The mass spectrum (MS) analysis was carried out using a LCT (Micromass®, UK) mass spectrometer with an ESI source. The percentage relative abundance was determined using quercetin as an internal standard (0.0625 μg/μl). Runs were performed in triplicate.
The cell lines used as cancer cells were K562, a human erythroleukemia and MCF7, a human breast adenocarcinoma, from the American Type Culture Collection (ATCC); and the cell lines used as normal cells were human peripheral blood mononuclear cells (PBMC) and human fibroblasts obtained from normal healthy donors after informed consent was given. This project was approved by the ethics committee (founded in 2002) of the Science Faculty at a meeting on August 21, 2007. The culture conditions under which the cell lines were maintained have already been reported .
The cytotoxic effects of the fractions and conventional chemotherapeutic drugs (doxorubicin, etoposide, vincristine and taxol) were evaluated using normal and tumor cells by means of trypan blue and the methylthiazol tetrazolium (MTT) assay, as previously reported . The P2Et fraction was dissolve in ethanol and the corresponding vehicle was used as a negative control.
The cells were treated with different concentrations of the P2Et fraction or valinomycin (positive control, 0.1 μg/ml) for 4, 8 and 12 h for K562 cells, and for 6, 12 and 24 h for MCF7 cells. The mitochondrial membrane potential (MMP) was measured using JC-1 dye, as previously described .
Phosphatidylserine (PS) externalization was assessed by flow cytometry using Annexin V-FITC (Molecular Probes, Invitrogen Corp, Carlsbad, CA, USA)/PI (Sigma, Saint Louis, MO, USA). K562 and MCF7 cells (3 × 105) were treated with doxorubicin, ethanol or the P2Et fraction for 48 h. After treatment, cells were suspended in Annexin buffer (Hepes 100 mM, NaCl 140 mM, CaCl2 2.5 mM) and incubated with Annexin V-FITC for 8 min at room temperature. Then the cells were incubated with PI for 2 min at 4°C, acquired on a FACSAria I (Becton Dickinson, New Jersey, USA) and analyzed with FlowJo software (Tree Star Inc., Ashland, USA). Results are expressed as the mean ± SE of three independent experiments.
Caspase 3 activity was estimated using the caspase 3 colorimetric assay kit, which detects enzyme activity based on the cleavage of Asp-Glu-Val-Asp (DEVD)-pNA (R&D Systems Inc., Minneapolis, MN, USA). Briefly, cells (2 × 105 cells/ml) were cultured using different concentrations of the P2Et fraction and doxorubicin (positive control) or ethanol (negative control) for 48 h. After the cells were ice lysed for 10 min the enzyme activity was measure on 96-well flat-bottom microplates with 50 μl of supernatant. The supernatant was prepared by centrifuging at 10,000 × g for 1 min (100-200 μg of total protein), and then adding 50 μl of reaction buffer supplemented with 10 μl of DTT and 5 μl of caspase 3 colorimetric substrate DEVD-pNA. Next cells were incubated for 1 ± 2 h at 37°C and caspase-3 activity was measured at 405 nm on a spectrophotometer (Multiskan Labsystem). The increase in caspase 3 activity was calculated relative to the absorbance value of the negative control.
DAPI (4',6-diamidino-2-phenylindole, Sigma) stained cells were monitored under a microscope as previously described . Slides were mounted using prolong anti-fade kit (Molecular Probes, Eugene, Oregon, USA) and cells were analyzed under a fluorescence microscope (Olympus, Japan). Cell cycle analysis was undertaken as previously reported .
The clonogenic assays were performed as previously described . Briefly, K562 human cells (2.5 × 105 cells/well) were plated (96-well plate) and treated with the P2Et fraction at 40 and 20 μg/ml, or with 15 and 6 μg/ml etoposide, or 0.2% ethanol (in PBS) and incubated for 24 h under a humidified environment at 37°C and 5% CO2. After treatment cells were re-plated onto 0.5% agar dishes (60 mm, 20,000 cells/dish), incubated for 14 days (37°C and 5% CO2) and stained with violet crystal (0.4% in ethanol). Cell colonies with more than 50 cells were counted. Treatments were performed in triplicate, and results expressed as mean ± SE.
P2Et fraction adjuvant activity was assessed using K562 and MCF7 cells in combination with the well-known cancer treatment drugs doxorubicin, vincristine, taxol and camptothecin. Cell viability was evaluated by means of the MTT assay. K562 and MCF7 cells (5 × 103 cells/well) were seeded in 96-well plates and treated for 6 h with sublethal concentrations of the P2Et fraction (1.6 μg/ml, 27 fold less than the IC50 value for K562 cells and 15.5 μg/ml for MCF7 cells); washed and incubated in fresh medium with each drug for 48 h at 37°C in humid atmosphere and 5% CO2. Sublethal concentrations of the chemotherapeutic drugs had been previously determined by MTT assay. Results are expressed as cell viability percentage relative to the control (100 × Treatment OD/Negative control OD).
Data is presented as the mean ± SE. The data were analyzed by one- and two-way ANOVA and differences between control and treated groups were determined using the Bonferroni and Tukey tests. Differences were considered significant for p < 0.05 and were determined using the GraphPad prism 5.0 software.
TLC analysis of the P2Et and S2Et fractions after hydrolysis revealed the presence of gallic acid visualized using UV (254 nm), ferric chloride and vainillin-sulfuric acid (VS) reagents (Figure 1A, B and 1C). Gallic acid retention (Rf) values in different solvent systems are shown in Figure 1D. The values are in agreement with those previously reported .
Chemical characterization of the most biological active fraction, P2Et, was carried out. The presence of gallic acid (after hydrolysis) was confirmed (data not shown) using proton nuclear magnetic resonance (H-NMR) spectroscopy. HPLC-PDA analysis revealed 17 peaks at 263 nm, and peaks having the highest absorbance display retention times of 3.32 and 3.78 min (Figure 1E). The peak molecular weights were calculated by means of mass spectrometry, and seven compounds were found to match with the molecular weights of compounds already published  for this species (Figure 1F and 1G, and Table 1). Clifford et al. reported the presence of gallotannins, ellagitannins, and galloylquinic acid tannins in C.spinosa fruits . In summary, the P2Et fraction was found to contain hydrolysable tannins such as galloylquinic acid derivatives at high percentages, and pentagalloylglucose and gallic acid-like compounds (gallates) at lower percentages.
Assessment of changes in K562 cell viability was carried out using trypan blue to select fractions derived from C. spinosa that had potential antitumor activity. Antitumor activity was found using the aqueous fraction at a concentration of 62.5 μg/ml, while the S2Et and P2Et fractions showed antitumor activity at a concentration of 15.6 μg/ml (Figure 2A). Assessment of changes in the appearance of intracellular vesicles, cell membrane morphology, nuclear alterations and the presence of necrotic cells were carried out by means of direct observation using a light microscope, and compared with etoposide activity as shown in Figure 2B.
In order to confirm cell viability the activity of mitochondria dehydrogenase was estimated using the MTT assay. The aqueous fraction induced cytotoxicity at a concentration of 62.5 μg/ml, while the S2Et and P2Et fractions induced cytotoxicity at concentrations of 31.2 and 15.6 μg/ml, respectively (Figure 2C). The P2Et fraction displayed significant cytotoxic activity in a dose-dependent manner. This finding was in agreement with those reported in previous studies on leukemia cells using chemically related P2Et tannins. Alkyl gallates and gallamides have been shown to exhibit cytotoxic activity with regard to murine lymphocyte leukemia cells (L1210) , and an acetone derived gallotannin-enriched fraction extracted from Eugenia jambos species was found to have a cytotoxic effect on promyelocytic leukemia HL-60 cells . The biological activity of tannins has been widely documented [6,17], but reports related to C. spinosa anti-tumoral activity are scarce. Gali-Muhtasib et al. found that hydrolysable tannins extracted from the fruit of C. spinosa decreased the level of skin cancer biochemical markers. In addition, there are reports describing anti-inflammatory and anti-microbial activity of tannins .
Additionally, the cytotoxic activity of C. spinosa fractions was evaluated using gingival fibroblasts from the oral mucosa or normal human mononuclear cells. The S2Et and aqueous fractions did not show cytotoxic activity with regard to the PHA-stimulated PBMCs or fibroblast cells, and the P2Et fraction had a slight cytotoxic effect at a concentration of 125 μg/ml on fibroblasts (Figure 2D and 2E). The IC50 values are shown in Table 2. However, it has been reported that 1-O-galloyl castalagin, casuarinin and gallotannins extracted from Eugenia jambos are cytotoxic to lymphocytes and to normal hepatic cells [16,18]. The decreased toxicity to normal cells and the specificity toward tumor cells was probably due to interactions among the fraction compounds. Evaluation of biological activity was continued only in the case of the P2Et fraction due to its superior biological results and the remarkable yield obtained during the extraction procedures.
Cell death analysis may help envisage the possible uses of the P2Et fraction in cancer treatment. Cytotoxic drugs can induce apoptosis by means of the mitochondrial pathway, inferring with MMP loss, effector caspases activation and DNA fragmentation . In order to determine if the P2Et fraction induces apoptosis and changes in MMP, K562 cells were treated with the P2Et fraction for 4, 8 and 12 h. Results showed that MMP loss occurred in a dose-dependent manner, starting at 4 h and continuing over a 12 h period (Figure 3A). Consequently, effector caspases activation may occur, which in fact was demonstrated in K562 cells after 48 h of treatment (Figure 3B). Finally, only a low percentage of cells displayed PS externalization (Figure 3C), suggesting that the loss in MMP was not followed by PS externalization; this was probably because the cells entered a different cell death process. Nonetheless, an early loss of MMP seems to be followed by DNA fragmentation (Figure 3D and 3E).
Loss of MMP induced by the P2Et fraction can be seen as an early apoptotic event that lasts for 12 h. These results correlated with previously described activity for alkyl gallates and gallamides having 8 to 12 carbon chains [6,18]. In addition, the P2Et fraction induced caspase 3 activation and DNA fragmentation, suggesting that after MMP loss, apoptotic cell death may be ongoing. However, since evidence of PS externalization was not found (Figure 3D), the decrease in long-term viability might be mediated by other cell death mechanisms.
Clonogenic ability is considered to be a gold standard test for determining the antitumor activity of extracted plant fractions as well as isolated compounds . K562 cells were treated with the P2Et fraction for 6 h and agar cultured for 14 days. Experimental data showed a significant decrease in the clonogenic ability of treated tumor cells as compared with the negative control (Figure 4). Indeed, a decrease in clonogenic ability also implies a decrease in long-term viability. Similar results were reported for PGG, a compound also present in the P2Et fraction, which is able to induce caspase-mediated apoptosis in the HL-60 cell line .
In order to determine if the P2Et fraction improves tumor cell sensitivity to the conventional cancer drugs doxorubicin, vincristine, camptothecin and taxol, a dose-response test was used to choose sub-optimal drugs and fraction concentrations as described in the Methods section. Separately, doxorubicin or the P2Et fraction at the tested concentrations showed a slight effect on cell viability, but when used in combination a significant decrease in cell viability was observed. In contrast, when treatment with the P2Et fraction was combined with vincristine or camptothecin, no positive effect was identified (Figure 5A). Therefore, it is worthwhile to point out that pretreatment with the P2Et fraction may be enhancing the cytotoxicity of taxol, highlighting a possible deleterious activity on taxanes when combined with the polyphenol fraction. On the contrary, in a similar analysis carried out on the breast cancer cell line MCF7, the P2Et fraction did exhibit adjuvant activity when combine with all the tested drugs (doxorubicin, vincristine, taxol and camptothecin, Figure 5B). Apoptotic cell death may not be associated with treatment with the P2Et fraction, since MMP loss and caspase 3 activity were not detected (Figure 6A and 6B) nor PS externalization found (Figure 6C). Instead, a slight cell cycle arrest in the G1 phase was observed when the P2Et fraction and doxorubicin treatments were combined at two different concentrations (Figure 6D), unlike the results achieved with the K562 cell line. The latter results suggest that P2Et adjuvant activity depends on the type of anticancer drug and the cancer cell line.
The use of natural products as adjuvants in antitumor therapy has been previously addressed; indeed, EGCG, a condensate tannin present in green tea, has been shown to sensitize cancer cells to taxol treatment in a breast cancer model . Also, it has been reported that EGCG (at low doses) and epicatechin gallate are not cytotoxic to a chemoresistant hepatocellular carcinoma, but in combination with doxorubicin, tumor cells were sensitized and a decrease in tumor size was seen in vivo using a doxorubicin-resistant liver cancer model . The C. spinosa fraction that was enriched in gallotannins not only exhibited cytotoxic activity, but also activity associated with conventional anti-cancer drugs, demonstrating once again the efficiency of natural products as potential sources of adjuvants that can be used in antitumor therapy. Herein, we described a C.spinosa derived fraction, P2Et, that was relatively easy to produce and which offered high yields in the extraction procedures; and preliminary cytotoxicity studies suggest that it can be used at very low dosages. In studies using several other cell lines (data not shown) a wide range of activities may be foreseen. Currently, the in vivo antitumor activity of the P2Et fraction is being evaluated and chemical characterization is being completed so that the molecular interactions may be scrutinized; and so that the cell death mechanism and the sensitization exerted by this fraction can be elucidated.
Our results suggest that the therapeutic efficacy of conventional chemotherapeutic drugs when combined with a blend of natural polyphenols may be increased in relation to leukemia or breast cancer cells. However, the molecular mechanisms underlying this activity have yet to be explained and are currently under study at our laboratory.
The authors declare that they have no competing interests.
The present work was conceived, directed and coordinated by SF. In vitro cytotoxicity assays, MMP measurements, Annexin V determinations, clonogenic assays, cell cycle analysis and cell line maintenance was undertaken by DC. Caspase 3 activity analysis and the DAPI DNA fragmentation test was carried out by CU. Plant fraction preparation, characterizations and statistical analysis were conducted by LMP. JH collaborated in the writing of the manuscript and analysis of the results. All of the authors have read the manuscript and agree with its contents.
The pre-publication history for this paper can be accessed here:
The authors thank the Science Faculty of the Pontificia Universidad Javeriana, Fundación Universitaria Juan N. Corpas for their support and the Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología "Francisco Jose de Caldas" (COLCIENCIAS) Bogotá, Colombia, for financial support.
|Chanwitheesuk A,Teerawutgulrag A,Kilburn J,Rakariyatham N,Antimicrobial gallic acid from Caesalpinia mimosoides lamkFood ChemYear: 20071001044104810.1016/j.foodchem.2005.11.008|
|Kloucek P,Polesny Z,Svobodova B,Vlkova E,Kokoska L,Antibacterial screening of some Peruvian medicinal plants used in Calleria DistrictJ EthnopharmacolYear: 200599230931210.1016/j.jep.2005.01.06215894143|
|Zhang J,Li L,Kim SH,Hagerman AE,Lu J,Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucosePharm ResYear: 20092692066208010.1007/s11095-009-9932-019575286|
|Clifford MN,Stoupi S,Kuhnert N,Profiling and characterization by LC-MSn of the galloylquinic acids of green tea, tara tannin, and tannic acidJ Agric Food ChemYear: 20075582797280710.1021/jf063533l17381119|
|Gali-Muhtasib HU,Yamout SZ,Sidani MM,Tannins protect against skin tumor promotion induced by ultraviolet-B radiation in hairless miceNutr CancYear: 2000371737710.1207/S15327914NC3701_9|
|Locatelli C,Rosso R,Santos-Silva MC,de Souza CA,Licinio MA,Leal P,Bazzo ML,Yunes RA,Creczynski-Pasa TB,Ester derivatives of gallic acid with potential toxicity toward L1210 leukemia cellsBioorg Med ChemYear: 20081673791379910.1016/j.bmc.2008.01.04918295493|
|Inoue M,Suzuki R,Koide T,Sakaguchi N,Ogihara Y,Yabu Y,Antioxidant, gallic acid, induces apoptosis in HL-60RG cellsBiochem Biophys Res CommunYear: 1994204289890410.1006/bbrc.1994.25447980558|
|Pellegrina CD,Padovani G,Mainente F,Zoccatelli G,Bissoli G,Mosconi S,Veneri G,Peruffo A,Andrighetto G,Rizzi C,et al. Anti-tumour potential of a gallic acid-containing phenolic fraction from Oenothera biennisCancer LettYear: 20052261172510.1016/j.canlet.2004.11.03316004929|
|Chia YC,Rajbanshi R,Calhoun C,Chiu RH,Anti-neoplastic effects of gallic acid, a major component of Toona sinensis leaf extract, on oral squamous carcinoma cellsMoleculesYear: 201015118377838910.3390/molecules1511837721081858|
|Shanafelt TD,Lee YK,Call TG,Nowakowski GS,Dingli D,Zent CS,Kay NE,Clinical effects of oral green tea extracts in four patients with low grade B-cell malignanciesLeuk ResYear: 200630670771210.1016/j.leukres.2005.10.02016325256|
|Kashiwada Y,Nonaka G,Nishioka I,Chang JJ,Lee KH,Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agentsJ Nat ProdYear: 19925581033104310.1021/np50086a0021431932|
|Kelkel M,Jacob C,Dicato M,Diederich M,Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignanciesMoleculesYear: 201015107035707410.3390/molecules1510703520944521|
|Chaudhari M,Mengi S,Evaluation of phytoconstituents of Terminalia arjuna for wound healing activity in ratsPhytother ResYear: 200620979980510.1002/ptr.185716835874|
|Uruena C,Cifuentes C,Castaneda D,Arango A,Kaur P,Asea A,Fiorentino S,Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cellsBMC Compl Alternative MedYear: 200886010.1186/1472-6882-8-60|
|Sharma OP,Bhat TK,Singh B,Thin-layer chromatography of gallic acid, methyl gallate, pyrogallol, phloroglucinol, catechol, resorcinol, hydroquinone, catechin, epicatechin, cinnamic acid, p-coumaric acid, ferulic acid and tannic acidJ Chrom AYear: 199882216717110.1016/S0021-9673(98)00490-7|
|Yang LL,Lee CY,Yen KY,Induction of apoptosis by hydrolyzable tannins from Eugenia jambos L. on human leukemia cellsCancer LettYear: 20001571657510.1016/S0304-3835(00)00477-810893444|
|Kim NS,Jeong SI,Hwang BS,Lee YE,Kang SH,Lee HC,Oh CH,Gallic acid inhibits cell viability and induces apoptosis in human monocytic cell line U937J Med FoodYear: 201114324024610.1089/jmf.2010.116021332403|
|Serrano A,Palacios C,Roy G,Cespon C,Villar ML,Nocito M,Gonzalez-Porque P,Derivatives of gallic acid induce apoptosis in tumoral cell lines and inhibit lymphocyte proliferationArch Biochem BiophysYear: 19983501495410.1006/abbi.1997.04749466819|
|Kroemer G,Galluzzi L,Vandenabeele P,Abrams J,Alnemri ES,Baehrecke EH,Blagosklonny MV,El-Deiry WS,Golstein P,Green DR,et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009Cell Death DifferYear: 200916131110.1038/cdd.2008.15018846107|
|Chen R,Gandhi V,Plunkett W,A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemiaCancer ResYear: 20066622109591096610.1158/0008-5472.CAN-06-121617108134|
|Pan MH,Lin JH,Lin-Shiau SY,Lin JK,Induction of apoptosis by penta-O-galloyl-beta-D-glucose through activation of caspase-3 in human leukemia HL-60 cellsEur J PharmacolYear: 19993812-317118310.1016/S0014-2999(99)00549-X10554885|
|Luo T,Wang J,Yin Y,Hua H,Jing J,Sun X,Li M,Zhang Y,Jiang Y,(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinomaBreast Cancer ResYear: 2010121R810.1186/bcr247320078855|
|Liang G,Tang A,Lin X,Li L,Zhang S,Huang Z,Tang H,Li QQ,Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancerInt J OncolYear: 201037111112320514403|
Compounds in the P2Et fraction.
|MS (m/z)||Reported m/z||Possible compounds||Relative abundance* (%)|
M/z ratio of C.spinosa reported compounds and compounds from the P2Et fraction matching the m/z ratio. The relative abundance is expressed as % of quercetin (internal standard)
IC50 values of C.spinosa fractions and drugs in tumor cell lines and normal cells (gingival fibroblasts and PBMC) estimated using the MTT assay. *Concentration (μg/ml) ± SE
|S2Et||> 125*||> 125*||> 125*|
|P2Et||44.50* ± 4.05||64.30* ± 1.00||> 125*|
|Aqueous||> 125*||> 125*||> 125*|
|Etoposide||15.60* ± 0.31||> 200*||> 200*|
|Doxorubicin||0.24* ± 0.14||5.80* ± 0.40||2023* ± 0.50|
|Taxol||1.14* ± 0.15||-||-|
|Vincristine||1.07* ± 0.28||0.07* ± 2.40||0.18* ± 2.00|
|Camptothecin||14.10* ± 3.70||-||-|
Keywords: Adjuvants, Gallotannins, C.spinosa, Tumor, Leukemia.
Previous Document: Charybdotoxin and margatoxin acting on the human voltage-gated potassium channel hKv1.3 and its H399...
Next Document: Brazilian solar saltworks - ancient uses and future possibilities.